Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: ASA404

First Posted Date: 2011-02-18

Last Posted Date: 2017-02-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 7

Registration Number: NCT01299701

Locations: 🇳🇿
Novartis Investigative Site, Grafton, Auckland, New Zealand

Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: Vadimezan™

First Posted Date: 2011-02-18

Last Posted Date: 2011-09-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT01299415

Locations: 🇺🇸
Cancer Therapy & Research Center, San Antonio, Texas, United States
🇺🇸
Masonic Cancer Center/ Clinical Trials Office, Minneapolis, Minnesota, United States
🇺🇸
Washington University School of Medicine/Siteman Cancer Center, St. Louis, Missouri, United States

and more 1 locations

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: BKM120

First Posted Date: 2011-02-16

Last Posted Date: 2016-03-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 63

Registration Number: NCT01297491

Locations: 🇺🇸
Washington University School of Medicine Washington University (16), St. Louis, Missouri, United States
🇺🇸
Fallon Clinic at Worcester Medical Center Fallon Clinic Worcester Med, Worcester, Massachusetts, United States
🇺🇸
Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology, Dallas, Texas, United States

and more 30 locations

Ranibizumab "Treat and Extend" in Diabetic Macular Edma

Phase 4

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Ranibizumab

First Posted Date: 2011-02-16

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 7

Registration Number: NCT01297569

Locations: 🇳🇴
Novartis Investigative Site, Oslo, Norway

Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: COPD

Interventions: Drug: placebo
Drug: tiotropium
Drug: indacaterol and glycopyrronium bromide (QVA149)

First Posted Date: 2011-02-11

Last Posted Date: 2013-03-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 85

Registration Number: NCT01294787

Locations: 🇪🇸
Novartis Investigative Site, Malaga, Spain

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Biological: Ofatumumab
Drug: Bendamustine

First Posted Date: 2011-02-11

Last Posted Date: 2018-08-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT01294579

Locations: 🇺🇸
Novartis Investigative Site, Yakima, Washington, United States

Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus

Phase 2

Completed

Conditions: Subacute Cutaneous Lupus Erythematosus

Interventions: Drug: KRP203 - 1.2mg
Drug: Placebo to KRP203 - 1.2 mg

First Posted Date: 2011-02-11

Last Posted Date: 2017-03-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT01294774

Locations: 🇮🇹
Novartis Investigative Site, Siena, SI, Italy

BEZ235 Trial in Patients With Advanced Endometrial Carcinoma

Phase 2

Withdrawn

Conditions: Endometrial Cancer

Interventions: Drug: BEZ235

First Posted Date: 2011-02-07

Last Posted Date: 2012-06-21

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01290406

Locations: 🇺🇸
Cancer Centers of North Carolina, Raleigh, North Carolina, United States
🇹🇷
Novartis Investigative Site, Istanbul, Turkey
🇺🇸
Cancer Care Northwest, Spokane, Washington, United States

and more 14 locations

A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies

Phase 1

Terminated

Conditions: Solid Tumor Malignancies

Interventions: Drug: ASA404, DMXAA, DXAA

First Posted Date: 2011-02-07

Last Posted Date: 2011-09-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT01290380

Locations: 🇺🇸
The University of Texas Science Center at Houston, Houston, Texas, United States
🇺🇸
University of Wisconsin & Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States

BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Phase 2

Completed

Conditions: Advanced Endometrial Cancer

Interventions: Drug: BKM120

First Posted Date: 2011-02-03

Last Posted Date: 2019-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 70

Registration Number: NCT01289041

Locations: 🇺🇸
St. Joseph's Hospital & Medical Center St Joseph's, Phoenix, Arizona, United States
🇺🇸
University of Oklahoma Health Sciences Center OU Health, Oklahoma City, Oklahoma, United States
🇺🇸
Sarah Cannon Research Institute SCRI (2), Nashville, Tennessee, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy